Riskpilot← Back to searchSign inGet full accessLoma Therapeutics ApS
APSActiveCVR 44226189Ole Maaløes Vej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20237 employees
Revenue 2024
DKK -2,1M
EBITDA margin
200.6%
Equity ratio
-89.6%
Financial strength
Net profit 2024
DKK -4,6M
7 employees
| Revenue | DKK -2,1M | — |
| EBITDA | DKK -4,3M | — |
| Net profit | DKK -4,6M | — |
| Total assets | DKK 5,1M | — |
| Equity | DKK -4,6M | — |
| Employees | 7 | — |
Legal name
Loma Therapeutics ApS
CVR number
44226189
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9. august 2023
Share capital
DKK 40.000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og et bestyrelsesmedlem i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at foretage forskning, udvikling og kommercialisering inden for medicinske produkter.
Address
Ole Maaløes Vej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | -2.143 |
| Staff expenses | -2.155 |
| EBITDA | -4.298 |
| Depreciation & amort. | -0 |
| EBIT | -4.298 |
| Net financials | -324 |
| Profit before tax | -4.622 |
| Tax | -0 |
| Net profit | -4.622 |
| Item | 2024 |
|---|---|
| Total assets | 5.113 |
| Equity | -4.582 |
| Long-term debt | 9.360 |
| Short-term debt | 334 |
| Total debt | 9.694 |
EBITDA margin
-429770800.0%
This company
15.8%
Market median
-2720068454% vs market
20242024
Equity ratio
-89.6%
This company
38.2%
Market median
-335% vs market
20242024
Return on equity
-462157000.0%
This company
18.4%
Market median
-2511722926% vs market
20242024
Net profit margin
-462157000.0%
This company
8.1%
Market median
-5705642075% vs market
20242024
Asset turnover
-0.42×
This company
1.12×
Market median
-138% vs market
20242024
Debt / equity
2.12×
This company
0.62×
Market median
-242% vs market
20242024
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
DR Management | Management | 2023 |
CT Founder | Founder | 2023 |
WH Founder | Founder | 2023 |
SH Management | Management | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33–49.99% | 33.33–49.99% | 2023 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2023 | |
| Company | 5–9.99% | 5–9.99% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Northgaard Holding ApS
Loma Therapeutics ApS Board members of Loma Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ditte Rahbæk Boilesen | Management | 0 companies |
| Christian Thirion | Founder | 0 companies |
| WFLAG Holding GmbH | Founder | 0 companies |
| Stephanie Holstein-Rønsbo | Management | 0 companies |
| Leif Helth Jensen | Board of Directors | 0 companies |
| Alejandra Maria Cristina Bonifacini Mørk | Chairman | 0 companies |
| Ralf Wagner | Board of Directors | 0 companies |
| Stuart John Myles Collinson | Board of Directors | 0 companies |